Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Pharmaceutical Investing

Paratek Pharmaceuticals (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results and provided an update on financial, clinical, and regulatory filing activities for the quarter and full year ended December 31, 2017. As quoted in the press release: “We had a strong finish …

As quoted in the press release:

“We had a strong finish to the year as we initiated our Phase 2 program in urinary tract infections and, importantly, we recently announced the completion of the rolling NDA submissions for omadacycline,” said Michael Bigham, Chairman and Chief Executive Officer, Paratek. “We continue to expand our commercial readiness activities for omadacycline as we await the FDA’s acceptance of our NDAs.”

Click here to read the full press release.

fda financial results nda paratek Pharmaceutical Investing